GET DAILY SIGNALSAllarity Therapeutics (ALLR) Holds Near $1 as Clinical Work Advances
Key Takeaways
- Allarity Therapeutics (ALLR) is a clinical-stage precision medicine company advancing stenoparib, a dual PARP/tankyrase inhibitor, alongside its proprietary Drug Response Predictor (DRP) companion diagnostic.
- Shares have been roughly flat over the last 30 days, consolidating near $1 after a volatile stretch that briefly pushed the stock below $0.87 in late October.
- Over the last three months the stock has declined about 19%, from near $1.27 in early August, and remains well below its 52-week high of roughly $1.84.
- Recent catalysts include a first commercial agreement under its CLIA laboratory services strategy, newly awarded patents, and expanded lab capabilities into proteomics and cell line research.
- As a micro-cap with roughly $15 million in market value, minimal revenue, and ongoing net losses, ALLR carries elevated clinical, financing, and dilution risk.
- For additional detail, explore Allarity's Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning across the market, explore Trending AI Robots.
Current Market Snapshot
ALLR trades near the lower portion of its 52-week range of approximately $0.77 to $1.84. With a market capitalization around $15 million and average daily volume in the low six figures, the stock behaves as a thinly traded micro-cap where modest order flow can produce outsized percentage swings. Over the last 30 days the shares have been essentially unchanged, while the longer three-month trend remains lower. This consolidation sits against a backdrop of steady news flow on the company's diagnostic platform and lead oncology program, rather than a single defining market event. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Allarity Therapeutics (ALLR) Business Overview and Competitive Position
Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company headquartered in Tarpon Springs, Florida. The company's lead asset is stenoparib, an orally available small molecule described as a dual PARP1/2 and tankyrase inhibitor. Stenoparib is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer and is also being evaluated in combination with temozolomide for relapsed small cell lung cancer.
Allarity's differentiating technology is its Drug Response Predictor (DRP) platform, which is designed to identify gene expression signatures that predict a tumor's sensitivity to a specific therapy. The company is developing stenoparib alongside a stenoparib-DRP companion diagnostic intended to select patients most likely to benefit from treatment. This pairing of a therapeutic with a companion diagnostic is central to Allarity's precision oncology strategy and its efforts to secure commercial exclusivity through both clinical data and intellectual property. From what I see, the DRP approach remains a key differentiator worth monitoring.
Recent Developments Driving ALLR
Several verified announcements have shaped investor sentiment around ALLR in recent weeks. The company reported its first revenue-generating contract under a newly established CLIA-certified laboratory services strategy, a step management frames as a potential path toward recurring revenue that complements its gene expression and DRP services. Allarity also disclosed progress on its DRP technology, including recently awarded patents intended to support the commercial exclusivity of stenoparib, and announced a granted Japanese patent for the stenoparib DRP companion diagnostic.
Separately, the company expanded its in-house laboratory capabilities to include proteomics and cell line research, aimed at deepening mechanism-of-action work for stenoparib and broadening external research opportunities. In its second-quarter 2026 update, Allarity reported completing the quarter with approximately $26.9 million in cash and restricted cash and finishing a Phase 3-ready stenoparib manufacturing campaign. The company also announced a strategic capital allocation toward the filing of a SPAC registration statement, a development that adds a layer of complexity to its financing outlook. I reviewed the latest filings using Tickeron’s AI Daily Buy/Sell Signals to cross-check the momentum signals.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important milestones for ALLR are clinical and financial. Investors should watch for updates on stenoparib's Phase 2 development in advanced recurrent ovarian cancer and the small cell lung cancer combination program, along with any additional companion diagnostic validation data. The company's next earnings report is estimated for mid-November 2026, and management's commentary on cash runway and financing plans will be closely scrutinized given the company's ongoing operating losses.
Regulatory and intellectual property developments, further commercialization of the CLIA laboratory services offering, and progress on the SPAC-related filing are additional factors that could influence sentiment. As with any clinical-stage micro-cap, dilution risk, binary clinical outcomes, and financing needs remain material considerations. Investors should weigh these drivers against the company's modest revenue base and negative cash flow when evaluating the stock. One thing that stands out is how the combination of DRP data and upcoming catalysts could shape the path forward.
Using Tickeron’s AI Trading Bots for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Trading Bots to test how automated strategies might respond to names like ALLR. The platform lets me compare different bot approaches across timeframes and performance metrics, which helps put the current consolidation into a broader, data-driven context without replacing my own fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALLR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ALLR turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 28 of 31 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALLR's RSI Indicator exited the oversold zone, 48 of 55 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ALLR as a result. In 50 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +1.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 31 cases where ALLR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALLR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.395) is normal, around the industry mean (3.104). P/E Ratio (-1.236) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement